avapritinib
blueprint medicines,illumina
['pathfinder', 'grail']
wood #aacr23 grail's pathfinder study. 6200 participants, 15 institutions. age &gt;50, history of cancer or smoking, another group average risk. 2021 ref overall signal 1.4%; high risk 1.5%. ppv 44.6%, 57.1% in high risk. most with dx resolution 57/63
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.